Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
Ford to Move Some Lincoln Production From China to U.S. in 2030 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Alphabet Shifts AI Strategy Toward Commercial Growth, Goldman Sachs Says 
Alphabet’s SpaceX Investment Soars 100-Fold to $94 Billion 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Add as a preferred source on Google
OXFORD, United Kingdom, March 27, 2017 -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, will be announcing its financial results for the fourth quarter and fiscal year ended 31 January 2017 on Wednesday, 29 March 2017.
Summit will host a conference call the same day at 1:00pm BST / 8:00am EDT. Conference call information will be included in the full year results press release and a replay of the call will also be available through the Company's website, www.summitplc.com.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit Therapeutics | |||
| Glyn Edwards / Richard Pye (UK office) Erik Ostrowski / Michelle Avery (US office) | Tel: | +44 (0)1235 443 951 +1 617 225 4455 | |
| Cairn Financial Advisers LLP | |||
| (Nominated Adviser) Liam Murray / Tony Rawlinson | Tel: | +44 (0)20 7213 0880 | |
| N+1 Singer | |||
| (Broker) Aubrey Powell / Jen Boorer | Tel: | +44 (0)20 7496 3000 | |
| MacDougall Biomedical Communications | |||
| (US media contact) | Tel: | +1 781 235 3060 | |
| Chris Erdman / Karen Sharma | [email protected] [email protected] | ||
| Consilium Strategic Communications | |||
| (Financial public relations, UK) | Tel: | +44 (0)20 3709 5700 | |
| Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Lindsey Neville | [email protected] | ||
-END-
